9-21971185-T-G

Variant summary

Our verdict is Benign. The variant received -10 ACMG points: 10P and 20B. PS1_Very_StrongPM1BP4_StrongBP6_Very_StrongBS1BS2

The NM_058195.4(CDKN2A):​c.217A>C​(p.Ser73Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000519 in 1,597,292 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely pathogenic in ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S73N) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0025 ( 1 hom., cov: 32)
Exomes 𝑓: 0.00031 ( 3 hom. )

Consequence

CDKN2A
NM_058195.4 missense

Scores

1
16

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:15O:1

Conservation

PhyloP100: -2.50

Publications

15 publications found
Variant links:
Genes affected
CDKN2A (HGNC:1787): (cyclin dependent kinase inhibitor 2A) This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
CDKN2A Gene-Disease associations (from GenCC):
  • melanoma, cutaneous malignant, susceptibility to, 2
    Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
  • melanoma-pancreatic cancer syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • familial atypical multiple mole melanoma syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • melanoma and neural system tumor syndrome
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -10 ACMG points.

PS1
Transcript NM_058195.4 (CDKN2A) is affected with MISSENSE_VARIANT having same AA change as one Pathogenic present in ClinVar.
PM1
In a hotspot region, there are 10 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 14 benign, 30 uncertain in NM_058195.4
BP4
Computational evidence support a benign effect (MetaRNN=0.0076120794).
BP6
Variant 9-21971185-T-G is Benign according to our data. Variant chr9-21971185-T-G is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 128200.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.0025 (380/152266) while in subpopulation AFR AF = 0.00871 (362/41572). AF 95% confidence interval is 0.00797. There are 1 homozygotes in GnomAd4. There are 181 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 380 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CDKN2ANM_058195.4 linkc.217A>C p.Ser73Arg missense_variant Exon 2 of 3 ENST00000579755.2 NP_478102.2
CDKN2ANM_000077.5 linkc.174A>C p.Arg58Arg synonymous_variant Exon 2 of 3 ENST00000304494.10 NP_000068.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CDKN2AENST00000579755.2 linkc.217A>C p.Ser73Arg missense_variant Exon 2 of 3 1 NM_058195.4 ENSP00000462950.1
CDKN2AENST00000304494.10 linkc.174A>C p.Arg58Arg synonymous_variant Exon 2 of 3 1 NM_000077.5 ENSP00000307101.5

Frequencies

GnomAD3 genomes
AF:
0.00248
AC:
377
AN:
152148
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00869
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000589
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000386
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.00191
GnomAD2 exomes
AF:
0.000693
AC:
152
AN:
219440
AF XY:
0.000483
show subpopulations
Gnomad AFR exome
AF:
0.0102
Gnomad AMR exome
AF:
0.000296
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000116
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000305
Gnomad OTH exome
AF:
0.000179
GnomAD4 exome
AF:
0.000311
AC:
449
AN:
1445026
Hom.:
3
Cov.:
31
AF XY:
0.000282
AC XY:
203
AN XY:
719232
show subpopulations
African (AFR)
AF:
0.0108
AC:
362
AN:
33388
American (AMR)
AF:
0.000314
AC:
14
AN:
44530
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26072
East Asian (EAS)
AF:
0.0000253
AC:
1
AN:
39542
South Asian (SAS)
AF:
0.0000466
AC:
4
AN:
85876
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
39186
Middle Eastern (MID)
AF:
0.00108
AC:
6
AN:
5574
European-Non Finnish (NFE)
AF:
0.0000153
AC:
17
AN:
1110764
Other (OTH)
AF:
0.000749
AC:
45
AN:
60094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.482
Heterozygous variant carriers
0
28
56
83
111
139
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00250
AC:
380
AN:
152266
Hom.:
1
Cov.:
32
AF XY:
0.00243
AC XY:
181
AN XY:
74450
show subpopulations
African (AFR)
AF:
0.00871
AC:
362
AN:
41572
American (AMR)
AF:
0.000588
AC:
9
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3472
East Asian (EAS)
AF:
0.000387
AC:
2
AN:
5166
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10608
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.0000294
AC:
2
AN:
67996
Other (OTH)
AF:
0.00237
AC:
5
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.507
Heterozygous variant carriers
0
20
40
60
80
100
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
10
20
30
40
50
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.142
Hom.:
2351
Bravo
AF:
0.00263
ESP6500AA
AF:
0.00617
AC:
25
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.000628
AC:
75
Asia WGS
AF:
0.00404
AC:
14
AN:
3478

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:15Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3Other:1
Jan 11, 2018
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.

Sep 19, 2013
ITMI
Significance:not provided
Review Status:no classification provided
Collection Method:reference population

Nov 09, 2021
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Mar 04, 2025
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not provided Benign:3
Jul 18, 2022
Quest Diagnostics Nichols Institute San Juan Capistrano
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Jul 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

CDKN2A: BP4, BS1, BS2

Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Melanoma-pancreatic cancer syndrome Benign:3
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Apr 20, 2023
Myriad Genetics, Inc.
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing.

Jul 28, 2016
Counsyl
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.

Hereditary cancer-predisposing syndrome Benign:3
Oct 20, 2020
Sema4, Sema4
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:curation

Mar 21, 2016
Color Diagnostics, LLC DBA Color Health
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Nov 04, 2015
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

General population or subpopulation frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance

Li-Fraumeni syndrome;C2931038:Familial pancreatic carcinoma Benign:1
Jul 04, 2024
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Melanoma, cutaneous malignant, susceptibility to, 2 Benign:1
Feb 01, 2025
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Familial melanoma Benign:1
Nov 01, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.049
BayesDel_addAF
Benign
-0.37
T
BayesDel_noAF
Benign
-0.30
CADD
Benign
2.3
DANN
Benign
0.83
DEOGEN2
Benign
0.0071
T;T
Eigen
Benign
-1.7
Eigen_PC
Benign
-1.7
FATHMM_MKL
Benign
0.028
N
LIST_S2
Benign
0.0
.;T
MetaRNN
Benign
0.0076
T;T
MetaSVM
Benign
-1.0
T
MutationAssessor
Benign
0.0
.;.
PhyloP100
-2.5
PrimateAI
Benign
0.41
T
PROVEAN
Benign
0.0
.;N
REVEL
Benign
0.0
Sift
Pathogenic
0.0
.;T
Sift4G
Benign
0.43
T;T
Vest4
0.31
ClinPred
0.0024
T
GERP RS
-4.5
PromoterAI
-0.029
Neutral
Mutation Taster
=24/76
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.020
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs201208890; hg19: chr9-21971184; API